Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182

Journal of Clinical Oncology

Volumn 33, Issue 8, 2015, Pages 937-943

  Horowitz, Neil S ^a   Miller, Austin ^b   Rungruang, Bunja ^c   Richard, Scott D ^d   Rodriguez, Noah ^f   Bookman, Michael A ^g   Hamilton, Chad A ^h   Krivak, Thomas C ^e   Maxwell, G Larry ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c AUGUSTA UNIVERSITY   (United States)

^d HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF ARIZONA   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ Department of Obsterics and Gynecology Inova Women's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GYNECOLOGIC SURGERY; KAPLAN MEIER METHOD; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; TIME FACTOR;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924940396     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3106     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A: Cancer Statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Reis LAG, Eisner MP, Kosary CL, et al: (eds): SEER Cancer Statistics Review, 1975-2001. http://www.seer.cancer.gov/csr/1975-2001/
3. Makar AP, Baekelandt M, Tropé CG, et al: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180, 1995
4. Eisenkop SM, Friedman RL, Wang H: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 69:103-106, 1998
5. Eisenkop SM, Spirtos NM: Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 82:435-441, 2001
6. Bristow RE, Tomacruz RS, Armstrong DK, et al: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20:1248-1259, 2002
7. Eisenkop SM, Spirtos NM, Friedman RL, et al: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 90:390-396, 2003
8. Chi DS, Eisenhauer EL, Lang J, et al: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559-564, 2006
9. Winter WE 3rd, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:3621-3627, 2007
10. Winter WE 3rd, Maxwell GL, Tian C, et al: Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 26:83-89, 2008
11. Aletti GD, Dowdy SC, Podratz KC, et al: Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol 197:676.e1-676.e7, 2007
12. Chi DS, Eisenhauer EL, Zivanovic O, et al: Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26-31, 2009
13. Hamilton CA, Miller A, Miller C, et al: The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A Gynecologic Oncology Group study. Gynecol Oncol 122:521-526, 2011
14. Hoskins WJ, Bundy BN, Thigpen JT, et al: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 47:159-166, 1992
15. Crawford SC, Vasey PA, Paul J, et al: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 23:8802-8811, 2005
16. Bookman MA, Brady MF, McGuire WP, et al: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425, 2009
17. Greenland S, Pearl J, Robins JM: Causal diagrams for epidemiologic research. Epidemiology 10:37-48, 1999
18. Berchuck A, Iversen ES, Lancaster JM, et al: Prediction of optimal versus suboptimal cytoreduction of advanced stage serous ovarian cancer with the use of microarray. Am J Obstet Gynecol 190:910-925, 2004
19. Bonome T, Levine DA, Shih J, et al: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68:5478-5486, 2008
20. Rodriguez N, Miller A, Richard SD, et al: Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: An analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol 130:487-492, 2013
21. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, et al: Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 46:102-109, 2010
22. Peiretti M, Zanagnolo V, Aletti GD, et al: Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncologic outcomes - Single institution experience. Gynecol Oncol 119:259-264, 2010
23. Chi DS, Zivanovic O, Levinson KL, et al: The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119:38-42, 2010
24. Vergote I, Tropé CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953, 2010
25. Chi DS, Musa F, Dao F, et al: An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 124:10-14, 2012
26. Bristow RE, Powell MA, Al-Hammadi N, et al: Disparities in ovarian cancer care quality and survival according to race and socioeconomic status. J Natl Cancer Inst 105:823-832, 2013
27. Aletti GD, Dowdy SC, Gostout BS, et al: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Am J Obstet Gynecol 107:77-85, 2006